Ensysce Biosciences, Inc. financial data

Symbol
ENSC on Nasdaq, ENSCW on OTC
Location
7946 IVanhoe Avenue, Suite 201, La Jolla, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 13, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 260 % +76.8%
Debt-to-equity 55.3 % -55.7%
Operating Margin -89.7 % +86.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 2.97M shares -65%
Common Stock, Shares, Outstanding 2.39M shares -70.6%
Common Stock, Value, Issued 241 USD -70.4%
Weighted Average Number of Shares Outstanding, Basic 2.2M shares +275%
Weighted Average Number of Shares Outstanding, Diluted 2.2M shares +275%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 7.41M USD +416%
Research and Development Expense 9.3M USD +58.4%
General and Administrative Expense 4.76M USD -8.88%
Operating Income (Loss) -6.65M USD +31.2%
Nonoperating Income (Expense) 68K USD
Earnings Per Share, Basic -2 USD/shares +97.4%
Earnings Per Share, Diluted -2 USD/shares +97.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 2.21M USD +112%
Other Assets, Current 241K USD +274%
Assets, Current 5.28M USD +115%
Other Assets, Noncurrent 293K USD -12.8%
Assets 5.57M USD +99.4%
Accounts Payable, Current 1.04M USD +116%
Liabilities, Current 2.51M USD +92.3%
Other Liabilities, Noncurrent 1.03K USD
Liabilities 2.51M USD +91%
Retained Earnings (Accumulated Deficit) -133M USD -5.2%
Stockholders' Equity Attributable to Parent 3.39M USD +87.5%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 3.06M USD +107%
Liabilities and Equity 5.57M USD +99.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.71M USD +49.9%
Net Cash Provided by (Used in) Financing Activities 1.26M USD -77.9%
Common Stock, Shares Authorized 250M shares 0%
Common Stock, Shares, Issued 2.39M shares -70.6%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -450K USD -120%
Depreciation 0 USD
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 1.5M shares 0%
Operating Lease, Payments 20.7K USD -9%
Additional Paid in Capital 137M USD +6.36%
Preferred Stock, Shares Outstanding 0 shares
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%